Srinivas Reddy Boreddy, Reshmi Nair, Prashant Kumar Pandey, Anshu Kuriakose, Shivakumar Bhadravathi Marigowda, Chaitali Dey, Arindam Banerjee, Hanumant Kulkarni, Milind Sagar, Shiv Ram Krishn, Shruthi Rao, Madhukara A R, Vinita Tiwari, Bhavna Alke, Prashantha Kumara Mv, Meena Shri, Chaitrali Dhamne, Sonal Patel, Pinky Sharma, Sankar Periyasamy, Jaya Bhatnagar, Moni Abraham Kuriakose, Ram Bhupal Reddy, Amritha Suresh, Suma Sreenivas, Nagaraja Govindappa, Praveen Reddy Moole, Usha Bughani, Seng-Lai Tan, Pradip Nair
The EGFR and TGF-β signalling pathways are important mediators of tumorigenesis, and crosstalk between them contributes to cancer progression and drug resistance. Therapies capable of simultaneously targeting EGFR and TGF-β could help improve patient outcomes across various cancer types. Here, we developed BCA101, an anti-EGFR IgG1 monoclonal antibody linked to an extracellular domain of human TGF-βRII. The TGF-β "trap" fused to the light chain in BCA101 did not sterically interfere with its ability to bind EGFR, inhibit cell proliferation, or mediate antibody-dependent cellular cytotoxicity...
April 19, 2023: Cancer Research